Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands.

Sara W QuistA J PostmaK J MyrénL A de JongM J Postma

Published in: The European journal of health economics : HEPAC : health economics in prevention and care (2023)

The cost reduction and QALY gain associated with the lower rates of BTH and less frequent administration make ravulizumab a cost-saving and clinically beneficial substitute for eculizumab for adults with PNH in the Netherlands.

Keyphrases

blood pressure
obstructive sleep apnea
depressive symptoms